Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2013, Article ID 824135, 6 pages
http://dx.doi.org/10.1155/2013/824135
Review Article

Similarities and Differences between the Pathogenesis and Pathophysiology of Diastolic and Systolic Heart Failure

Cardiovascular Division, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan

Received 19 August 2013; Revised 8 October 2013; Accepted 10 October 2013

Academic Editor: Dirk Westermann

Copyright © 2013 Kazuo Komamura. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Ouzounian, D. S. Lee, and P. P. Liu, “Diastolic heart failure: mechanisms and controversies,” Nature Clinical Practice Cardiovascular Medicine, vol. 5, pp. 375–386, 2008. View at Google Scholar
  2. M. T. Maeder and D. M. Kaye, “Heart failure with normal left ventricular ejection fraction,” Journal of the American College of Cardiology, vol. 53, no. 11, pp. 905–918, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. B. A. Borlaug and W. J. Paulus, “Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment,” European Heart Journal, vol. 32, no. 6, pp. 670–679, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. E. H. García, E. R. Perna, E. F. Farías et al., “Reduced systolic performance by tissue Doppler in patients with preserved and abnormal ejection fraction: new insights in chronic heart failure,” International Journal of Cardiology, vol. 108, no. 2, pp. 181–188, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Yip, M. Wang, Y. Zhang, J. W. H. Fung, P. Y. Ho, and J. E. Sanderson, “Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition?” Heart, vol. 87, no. 2, pp. 121–125, 2002. View at Google Scholar · View at Scopus
  6. S. J. Skaluba and S. E. Litwin, “Mechanisms of exercise intolerance: insights from tissue Doppler imaging,” Circulation, vol. 109, no. 8, pp. 972–977, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Yamamoto, Y. Sakata, T. Ohtani, Y. Takeda, and T. Mano, “Heart failure with preserved ejection fraction: what is known and unknown,” Circulation Journal, vol. 73, no. 3, pp. 404–410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. A. Hunt, W. T. Abraham, M. H. Chin et al., “ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society,” Circulation, vol. 112, no. 12, pp. e154–e235, 2005. View at Google Scholar · View at Scopus
  9. R. S. Vasan and D. Levy, “Defining diastolic heart failure: a call for standardized diagnostic criteria,” Circulation, vol. 101, no. 17, pp. 2118–2121, 2000. View at Google Scholar · View at Scopus
  10. M. R. Zile, W. H. Gaasch, J. D. Carroll et al., “Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?” Circulation, vol. 104, no. 7, pp. 779–782, 2001. View at Google Scholar · View at Scopus
  11. M. R. Zile, C. F. Baicu, and W. H. Gaasch, “Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle,” The New England Journal of Medicine, vol. 350, no. 19, pp. 1953–1959, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. T. E. Owan, D. O. Hodge, R. M. Herges, S. J. Jacobsen, V. L. Roger, and M. M. Redfield, “Trends in prevalence and outcome of heart failure with preserved ejection fraction,” The New England Journal of Medicine, vol. 355, no. 3, pp. 251–259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. R. S. Bhatia, J. V. Tu, D. S. Lee et al., “Outcome of heart failure with preserved ejection fraction in a population-based study,” The New England Journal of Medicine, vol. 355, no. 3, pp. 260–269, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. S. F. Nagueh, C. P. Appleton, T. C. Gillebert et al., “Recommendations for the evaluation of left ventricular diastolic function by echocardiography,” European Journal of Echocardiography, vol. 10, no. 2, pp. 165–193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. D. J. van Veldhuisen, G. C. Linssen, T. Jaarsma et al., “B-type natriuretic Peptide and prognosis in heart failure patients with preserved and reduced ejection fraction,” Journal of the American College of Cardiology, vol. 61, no. 14, pp. 1498–1506, 2013. View at Google Scholar
  16. F. P. Brouwers, R. A. de Boer, P. van der Harst et al., “Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND,” European Heart Journal, vol. 34, pp. 1424–1431, 2013. View at Google Scholar
  17. R. Santhanakrishnan, J. P. Chong, T. P. Ng et al., “Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction,” European Journal of Heart Failure, vol. 14, pp. 1338–1347, 2012. View at Google Scholar
  18. R. R. J. van Kimmenade and J. L. Januzzi Jr., “Emerging biomarkers in heart failure,” Clinical Chemistry, vol. 58, no. 1, pp. 127–138, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. H. K. Gaggin and J. L. Januzzi Jr., “Biomarkers and diagnostics in heart failure,” Biochimica et Biophysica Acta, 2013. View at Publisher · View at Google Scholar
  20. J. G. F. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, and J. Taylor, “The perindopril in elderly people with chronic heart failure (PEP-CHF) study,” European Heart Journal, vol. 27, no. 19, pp. 2338–2345, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Yusuf, M. A. Pfeffer, K. Swedberg et al., “Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial,” The Lancet, vol. 362, no. 9386, pp. 777–781, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. B. M. Massie, P. E. Carson, J. J. McMurray et al., “Irbesartan in patients with heart failure and preserved ejection fraction,” The New England Journal of Medicine, vol. 359, no. 23, pp. 2456–2467, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. F. Hernandez, B. G. Hammill, C. M. O'Connor, K. A. Schulman, L. H. Curtis, and G. C. Fonarow, “Clinical effectiveness of beta-blockers in heart failure. Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry,” Journal of the American College of Cardiology, vol. 53, no. 2, pp. 184–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Fukuta, D. C. Sane, S. Brucks, and W. C. Little, “Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report,” Circulation, vol. 112, no. 3, pp. 357–363, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. W. J. Paulus and J. J. M. van Ballegoij, “Treatment of heart failure with normal ejection fraction: an inconvenient truth!,” Journal of the American College of Cardiology, vol. 55, no. 6, pp. 526–537, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. B. A. Borlaug, V. Melenovsky, T. Marhin, P. Fitzgerald, and D. A. Kass, “Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans,” Circulation, vol. 112, no. 17, pp. 2642–2649, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Vlachopoulos, K. Hirata, and M. F. O'Rourke, “Effect of sildenafil on arterial stiffness and wave reflection,” Vascular Medicine, vol. 8, no. 4, pp. 243–248, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. S. D. Katz, K. Balidemaj, S. Homma, H. Wu, J. Wang, and S. Maybaum, “Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure,” Journal of the American College of Cardiology, vol. 36, no. 3, pp. 845–851, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. G. D. Lewis, J. Lachmann, J. Camuso et al., “Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure,” Circulation, vol. 115, no. 1, pp. 59–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. H. H. Chen, “Heart failure: a state of brain natriuretic peptide deficiency or resistance or both!,” Journal of the American College of Cardiology, vol. 49, no. 10, pp. 1089–1091, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. M. Redfield, K. L. Lee, and E. Braunwald, “Evaluating the effectiveness of Sildenafil at improving health outcomes and exercise ability in people with diastolic heart failure (The RELAX Study),” NCT00763867, 2008, http://clinicaltrials.gov/.
  32. K. R. Daniel, G. Wells, K. Stewart, B. Moore, and D. W. Kitzman, “Effect of aldosterone antagonism on exercise tolerance, doppler diastolic function, and quality of life in older women with diastolic heart failure,” Congestive Heart Failure, vol. 15, no. 2, pp. 68–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. P. V. Vaitkevicius, M. Lane, H. Spurgeon et al., “A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 3, pp. 1171–1175, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. D. A. Kass, E. P. Shapiro, M. Kawaguchi et al., “Improved arterial compliance by a novel advanced glycation end-product crosslink breaker,” Circulation, vol. 104, no. 13, pp. 1464–1470, 2001. View at Google Scholar · View at Scopus
  35. W. C. Little, M. R. Zile, D. W. Kitzman, W. G. Hundley, T. X. O'Brien, and R. C. Degroof, “The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure,” Journal of Cardiac Failure, vol. 11, no. 3, pp. 191–195, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. B. A. Borlaug, V. Melenovsky, S. D. Russell et al., “Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction,” Circulation, vol. 114, no. 20, pp. 2138–2147, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. T. T. Phan, K. Abozguia, G. Nallur Shivu et al., “Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency,” Journal of the American College of Cardiology, vol. 54, no. 5, pp. 402–409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. D. W. Kitzman, M. B. Higginbotham, F. R. Cobb, K. H. Sheikh, and M. J. Sullivan, “Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism,” Journal of the American College of Cardiology, vol. 17, no. 5, pp. 1065–1072, 1991. View at Google Scholar · View at Scopus
  39. C. S. Smith, P. A. Bottomley, S. P. Schulman, G. Gerstenblith, and R. G. Weiss, “Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium,” Circulation, vol. 114, no. 11, pp. 1151–1158, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Frenneaux, “Perhexiline therapy in heart failure with preserved ejection fraction syndrome,” NCT00839228, 2009, http://clinicaltrials.gov/.